---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-010493"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:12:57.478698+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zomedica Q2 revenue up 43% to $6.0M; net loss flat at $5.3M; cash $142.4M

## Summary
- Revenue $6.0M vs $4.2M YoY (+43%); therapeutic segment $5.8M (+38%), diagnostic $0.2M (+100%).
- Net loss $5.3M ($0.005/sh) unchanged YoY; adjusted non-GAAP EBITDA loss $3.1M.
- Cash & equivalents $142.4M, down from $186.8M YoY; normalized operating burn ~$3M.
- Gross margin 67%; adjusted >70% excluding one-time costs; consumable revenue $4.0M (+48% YoY).
- Due diligence on potential SMP (VetGuardian) acquisition progressing; TRUVIEW digital microscopy launched late June.

## SEC filing metadata
- accession: 0001654954-23-010493
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495423010493/0001654954-23-010493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495423010493/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-010493
- JSON: https://secwatch.observer/filing/0001654954-23-010493.json
- Plain text: https://secwatch.observer/filing/0001654954-23-010493.txt

## Key facts
- Earnings Releases
  Zomedica Corp. reported the quarter ended June 30, 2023 results: revenue $6.0 million.
  - Period: the quarter ended June 30, 2023
  - Revenue: $6.0 million
  - Result: reported results
  source text: or incorporated by reference therein. --- EX-99.1 (EX-99.1) --- zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Second Quarter 2023 Financial Results: Revenue up 43% to $6.0 Million; Strong 67% Gross Margin & $142.4 Million in Liquidity ANN ARBOR, MI / ACCESSWIRE / August 10, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1684144/000165495423010493/0001654954-23-010493-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.